Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1050 participants.
Also called NCT07324837
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,050 participants
- Sponsor
- Registry
-
NCT07324837
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Recruiting
Technical summary
Registry record NCT07324837. Randomized; triple masking; primary purpose treatment. Start 2026-06-09 (actual); primary completion 2028-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
- Acronym
- FRIDA-CT
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- non-immunogenic staphylokinase
- Intervention (Drug)
- Placebo
- Lead sponsor
- Supergene, LLC
Record details
- Record id
cardio:ct-nct07324837- Content hash
71e0dfdcf4755c0d943d9f106d7b199a7c047b871726d86292ba21aa8590e598